MedTrace Logo

The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients

NCT02149914 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2014-11-20

No results posted yet for this study

Summary

Gastroesophageal reflux disease(GERD) mainly related to the reflux of stomach content induced by the dysfunction of lower esophageal sphincter. Proton pump inhibitors (PPI) can effectively block gastric acid secretion but the drug reactions and the degree of improvement in symptoms are sometimes unpredictable. The aim of this study is to investigate the association between the clinical efficacy of PPI in patients with GERD and the personal physical status by Ryodoraku and ANSWatch.

Conditions

  • Non-erosive Reflux Disease
  • Barrett's Esophagus

Interventions

DEVICE

Ryodoraku

Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication

DEVICE

ANSWatch

ANSWatch to assess the autonomic nervous system for each patient before and after taking the medication

DEVICE

UGI endoscopy

UGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication

OTHER

GerdQ

GerdQ to assess the severity of GERD for each patient before and after taking the medication

DRUG

PPI

Sponsors & Collaborators

  • Taichung Tzu Chi Hospital

    lead OTHER

Principal Investigators

  • Mei-Ling Shen, M.D · Taichung Tzu Chi Hospital

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02149914 on ClinicalTrials.gov